Trinean to In-License PerkinElmer Technology
News Feb 04, 2013
Under the agreement, Trinean obtained a license for the design and development of microfluidic cartridges and instruments in the field of UV/VIS quantification of lightabsorbing substances for certain life sciences research applications.
“We are very pleased with this agreement between PerkinElmer and Trinean. The combined IP from Trinean and PerkinElmer will boost the expansion of our platform for DNA, RNA and protein quantification and quality control," said Philippe Stas, CEO of Trinean. "Our microfluidic chips generate high quality UV/Vis spectral absorbance profiles of bio-molecules. They are designed to meet the requirements of labs requiring speed and minimal sample usage. Our unmatched large measurement range allows quantification of undiluted protein samples in real-time thereby significantly shortening the purification process.”
"The use of microfluidics for UV/Vis spectrometry is an exciting market development," said Kevin Hrusovsky, Life Sciences President, PerkinElmer. "We continue to leverage our microfluidics portfolio through licensing collaborations such as our agreement with Trinean to extend our market reach and create additional revenue opportunities."
Biomillenia Leverages QIAGEN Bioinformatics in Microbiome-on-a-Chip Discovery of Unculturable MicrobesNews
Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits. QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes.READ MORE
Fast, Accurate Parasite Detection Method DevelopedNews
A research team from the University of Macau has developed a fast, accurate, and convenient point-of-care pathogen detection method with the help of a digital microfluidic system.READ MORE
Cell-weighing Method Could Help Doctors Choose Cancer DrugsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE